IMS CORE lab teams up with Cristal Therapeutics
Cristal Therapeutics has announced that it has secured a Horizon 2020 grant. This allows the company to further develop the CriPec Nanomedicine Platform. This will be done in collaboration with the IMS CORE lab at Maastricht University’s M4I Division of Imaging Mass Spectrometry.
Cristal Therapeutics is a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases. The ICARUS project will be carried out in close collaboration with the IMS CORE lab at the division of Imaging Mass Spectrometry, where CriPec® nanoparticle microlocalisation and drug release in tumours will be evaluated. Mass spectrometry imaging, technology together with Cristal Therapeutics’ expert team, will provide critical new insights to optimally design CriPec® nanomedicines with the aim of achieve superior therapeutic profiles.
The project at M4I will be led by Dr. Berta Cillero Pastor and by Prof. Ron Heeren.
For more details, read the full article on the Cristal Therapeutics website: http://cristaltherapeutics.com/cristal-therapeutics-awarded-horizon-2020-grant-to-further-develop-the-cripec-nanomedicine-platform/
Also read
-
Paula Roldán Barraza will join METRO as a PhD researcher. She will be based both at SBE and at LAW and will be supervised by Iwan Bos (SBE), Niels Philipsen (METRO) and Kalpana Tyagi (IGIR).
-
Hüseyin Sakalli, a teacher at FASoS, has developed a new card game designed to support the PBL process. Are you curious? Read his story!
-
Professor Andrea Ott successfully applied for a a Jean Monnet Centre of Excellence on Crises and Emergencies in EU Integration (EmergEU) in July 2024. In the upcoming three years, the centre will explore crises and emergencies in EU integration.
